Gingival Recession, Mucogingival SurgeryNCT07529340
Study of Hyaluronic Acid Used With Gum Surgery to Treat Gum Recession in Adults
A study testing Coronally Advanced Flap with Connective Tissue Graft and Cross-linked Hyaluronic Acid Gel in people with Gingival Recession, Mucogingival Surgery, run by Universidade do Porto at 1 site in Portugal.
Trial summary
Gingival recession is a common condition in which the gum tissue recedes, exposing the root surface of the tooth. This can lead to tooth sensitivity, higher risk of root decay, and aesthetic concerns. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gingival Recession, Mucogingival Surgery
- What is being tested?
- Coronally Advanced Flap with Connective Tissue Graft and Cross-linked Hyaluronic Acid Gel
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 sitePortugal
- Study dates
- May 2026to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- - Age ≥ 18 years, in good general health (ASA I or II)
- Presence of a single gingival recession defect classified as RT1 or RT2
- Recession depth ≥ 2 mm with identifiable cemento-enamel junction (CEJ)
- Presence of at least 1 mm of keratinized tissue at the defect site
- No active periodontal disease (probing depth ≤ 4 mm and no bleeding on probing at the selected tooth)
- Full-Mouth Plaque Score (FMPS ≤ 20%) and Full-Mouth Bleeding Score (FMBS ≤ 20%)
Show all 10Show fewer
- Vital tooth without caries, cervical lesions, or defective restorations
- Good oral hygiene and motivation to maintain plaque control
- Ability and willingness to comply with study procedures
- Signed informed consent
Who cannot join
- Uncontrolled systemic diseases (e.g., uncontrolled diabetes, severe cardiovascular disease, immunodeficiency)
- Pregnant or breastfeeding women
- Autoimmune diseases or immunosuppressive therapy
- Known hypersensitivity to hyaluronic acid
- Heavy smokers (>10 cigarettes/day) or recent tobacco use
- Active periodontal disease at the study site
Show all 13Show fewer
- Caries, root fractures, endodontic lesions, or defective restorations at the study tooth
- Previous mucogingival surgery at the study site
- Recent use of antibiotics, corticosteroids, or anti-inflammatory drugs
- Coagulation disorders or anticoagulant therapy contraindicating surgery
- Hormonal disorders affecting wound healing
- Acute oral infections
- Any condition that may interfere with study participation or follow-up
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Portugal1 site
CEPI - Clinical Center for Periodontology and Implantology
Porto, Porto District, 4350-110
Marta M Abreu-Costa, +351911834256, martacostaa11@gmail.com
About this study
Official title: Effectiveness of Hyaluronic Acid Application in Coronally Advanced Flap Combined With a Subepithelial Connective Tissue Graft Versus Coronally Advanced Flap Combined With a Subepithelial Connective Tissue Graft Alone: A Clinical Trial
Gingival recession is a common condition in which the gum tissue recedes, exposing the root surface of the tooth. This can lead to tooth sensitivity, higher risk of root decay, and aesthetic concerns. A commonly used surgical treatment is the coronally advanced flap combined with a connective tissue graft (CAF + SCTG), which aims to cover the exposed root and improve gum health.
Hyaluronic acid (HA) is a naturally occurring substance in the body that plays an important role in wound healing. It may help improve tissue repair, reduce inflammation, and enhance healing after surgery.
Read more
This study aims to evaluate whether the use of hyaluronic acid (hyaDENT BG®) in addition to standard surgical treatment improves clinical outcomes in patients with gingival recession. Participants will be randomly assigned to receive either standard treatment alone or standard treatment with hyaluronic acid.
The main outcome is the proportion of sites with complete root coverage after 12 months. Additional outcomes include healing, gum tissue improvement, patient-reported pain and discomfort, and aesthetic results.
The study also includes a laboratory component to investigate how hyaluronic acid affects cells involved in gum healing.
Read the detailed description
Gingival recession (GR) is a common mucogingival condition characterized by apical displacement of the gingival margin beyond the cemento-enamel junction, leading to root exposure, dentin hypersensitivity, increased risk of root caries, and aesthetic impairment. The coronally advanced flap combined with a subepithelial connective tissue graft (CAF + SCTG) is considered the gold standard for the treatment of single gingival recession defects, providing predictable root coverage and long-term stability. However, postoperative morbidity, donor-site discomfort, and incomplete root coverage may still occur.
Hyaluronic acid (HA) is a key component of the extracellular matrix with biological properties that promote wound healing, including stimulation of angiogenesis, cell migration, proliferation, and modulation of inflammatory responses. Cross-linked HA formulations exhibit prolonged bioactivity and may enhance soft tissue healing and regeneration in periodontal surgery.
This study is a prospective, randomized, controlled, post-market clinical follow-up (PMCF) trial designed to evaluate the clinical effectiveness and safety of adjunctive cross-linked hyaluronic acid (hyaDENT BG®) in combination with CAF + SCTG for the treatment of single RT1 and RT2 gingival recession defects. A total of 34 patients will be enrolled and randomly allocated in a 1:1 ratio to either the test group (CAF + SCTG with adjunctive HA) or the control group (CAF + SCTG alone). Randomization will be stratified by recession type (RT1 vs RT2), and outcome assessors will be blinded to treatment allocation.
The primary endpoint is complete root coverage (CRC) at 12 months, defined as recession depth equal to 0 mm relative to the cemento-enamel junction. Secondary endpoints include mean root coverage, recession reduction, clinical attachment level gain, probing depth reduction, keratinized tissue gain, early wound healing (Early Wound Healing Score), patient-reported outcomes (pain, discomfort, and oral health-related quality of life), and aesthetic outcomes assessed using the Root Coverage Esthetic Score (RES).
Clinical assessments will be performed at baseline and at predefined follow-up visits up to 12 months post-surgery using standardized protocols and calibrated examiners. Patient-reported outcomes will be collected using validated instruments, including visual analog scales (VAS) and the OHIP-14 questionnaire.
In parallel, an in vitro component will be conducted using primary human gingival fibroblasts isolated from connective tissue grafts obtained during surgery. These cells will be used to evaluate the effects of HA on cell viability, proliferation, migration, gene expression related to wound healing and inflammation, and activation of intracellular signaling pathways.
This combined clinical and translational approach aims to provide comprehensive evidence on both the clinical performance and biological mechanisms of action of hyaluronic acid in periodontal plastic surgery.
- Conditions
- Gingival Recession, Mucogingival Surgery
- Being tested
- Coronally Advanced Flap with Connective Tissue Graft, Cross-linked Hyaluronic Acid Gel
- Keywords
- Gingival recession, Coronally advanced flap, Connective tissue graft, Hyaluronic acid, Mucogingival surgery
- Medical subject headings
- Gingival Recession
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronally Advanced Flap with Connective Tissue GraftProcedure or surgery
Also called CAF + SCTG
Standard periodontal plastic surgery procedure for root coverage involving coronally advanced flap (CAF) combined with a subepithelial connective tissue graft (SCTG). The technique aims to cover exposed root surfaces and improve soft tissue thickness and stability.
Cross-linked Hyaluronic Acid GelDevice
Also called hyaDENT BG®
Application of cross-linked hyaluronic acid gel (hyaDENT BG®) as an adjunct to periodontal surgery. The gel is applied to the recipient site and used to immerse the connective tissue graft prior to placement, aiming to enhance soft tissue healing, promote cell proliferation and angiogenesis, and improve clinical outcomes.
| Study group | Role | What they receive |
|---|---|---|
| CAF + SCTG + Hyaluronic Acid | Experimental | Participants undergo coronally advanced flap (CAF) surgery combined with a subepithelial connective tissue graft (SCTG) with adjunctive application of cross-linked hyaluronic acid (hyaDENT BG®). The graft is immersed in hyaluronic acid prior to placement, and the gel is applied to the recipient site before flap closure. Receives: Procedure: Coronally Advanced Flap with Connective Tissue Graft; Device: Cross-linked Hyaluronic Acid Gel |
| CAF + SCTG | Active comparator | Participants undergo coronally advanced flap (CAF) surgery combined with a subepithelial connective tissue graft (SCTG) without adjunctive hyaluronic acid. The graft is handled under standard conditions and hydrated with sterile saline prior to placement. Receives: Procedure: Coronally Advanced Flap with Connective Tissue Graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete Root Coverage (CRC)
Proportion of treated sites achieving complete root coverage, defined as recession depth equal to 0 mm relative to the cemento-enamel junction, assessed using a calibrated periodontal probe by a blinded examiner.
Measured: 12 months
Secondary outcomes (10)
Mean Root Coverage (MRC)
Percentage of root coverage achieved relative to baseline recession depth at the treated site.
Measured: 12 months
Recession Reduction (RecRed)
Change in gingival recession depth (mm) from baseline to follow-up, measured using a calibrated periodontal probe.
Measured: 12 months
Clinical Attachment Level (CAL) Gain
Change in clinical attachment level (mm) from baseline to 12 months, measured using a periodontal probe.
Measured: 12 months
Probing Depth (PD) Reduction
Reduction in probing depth (mm) from baseline to 12 months, measured using a periodontal probe.
Measured: 12 months
Keratinized Tissue Width (KT) Gain
Increase in the width of keratinized gingiva (mm) from baseline to follow-up.
Measured: 12 months
Early Wound Healing Score (EHS)
Assessment of early soft tissue healing using the Early Wound Healing Score at predefined postoperative time points.
Measured: 3 days, 14 days, and 6 weeks
Postoperative Pain and Discomfort (VAS)
Patient-reported pain and discomfort assessed using a visual analog scale (VAS).
Measured: 3 days, 14 days, and 6 weeks
Oral Health-Related Quality of Life (OHIP-14)
Patient-reported oral health-related quality of life measured using the OHIP-14 questionnaire.
Measured: 3 days, 14 days, and 6 weeks
Root Coverage Esthetic Score (RES)
Esthetic outcome assessed using the Root Coverage Esthetic Score based on standardized clinical photographs.
Measured: 12 months
Surgical and Postoperative Complications
Incidence of intraoperative and postoperative complications, including flap dehiscence, infection, or graft necrosis.
Measured: up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study startMay 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Gingival Recession, Mucogingival SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 34 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidade do Porto
- Sponsor type
- University, hospital or other
- Collaborators
- Regedent AG, Zürich
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07529340
- Sponsor's protocol ID
- 24/2023
- Status last verified
- Mar 2026
- First submitted
- 7 Apr 2026
- Last updated
- 20 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: No final decision has been made regarding individual participant data sharing. Data sharing will be considered in accordance with applicable regulations and institutional policies.
Publications
Guldener K, Lanzrein C, Eliezer M, Katsaros C, Stahli A, Sculean A. Treatment of single mandibular recessions with the modified coronally advanced tunnel or laterally closed tunnel, hyaluronic acid, and subepithelial connective tissue graft: a report of 12 cases. Quintessence Int. 2020;51(6):456-463. doi: 10.3290/j.qi.a44492.
PubMed 32368762Asparuhova MB, Kiryak D, Eliezer M, Mihov D, Sculean A. Activity of two hyaluronan preparations on primary human oral fibroblasts. J Periodontal Res. 2019 Feb;54(1):33-45. doi: 10.1111/jre.12602. Epub 2018 Sep 27.
PubMed 30264516Pilloni A, Schmidlin PR, Sahrmann P, Sculean A, Rojas MA. Effectiveness of adjunctive hyaluronic acid application in coronally advanced flap in Miller class I single gingival recession sites: a randomized controlled clinical trial. Clin Oral Investig. 2019 Mar;23(3):1133-1141. doi: 10.1007/s00784-018-2537-4. Epub 2018 Jun 30.
PubMed 29961138
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Hyaluronic Acid Application in Coronally Advanced Flap Combined With a Subepithelial Connective Tissue Graft Versus Coronally Advanced Flap Combined With a Subepithelial Connective Tissue Graft Alone: A Clinical Trial
- ClinicalTrials.gov ID
- NCT07529340
- Acronym / sponsor ID
- 24/2023
- Conditions
- Gingival Recession, Mucogingival Surgery
- Keywords
- Gingival recession, Coronally advanced flap, Connective tissue graft, Hyaluronic acid, Mucogingival surgery
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 34 participants (estimated)
- Lead sponsor
- Universidade do PortoUniversity, hospital or other
- Collaborators
- Regedent AG, Zürich
- Study start
- May 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 14 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Gingival recession is a common condition in which the gum tissue recedes, exposing the root surface of the tooth. This can lead to tooth sensitivity, higher risk of root decay, and aesthetic concerns. A commonly used surgical treatment is the coronally advanced flap combined with a connective tissue graft (CAF + SCTG), which aims to cover the exposed root and improve gum health.
Hyaluronic acid (HA) is a naturally occurring substance in the body that plays an important role in wound healing. It may help improve tissue repair, reduce inflammation, and enhance healing after surgery.
This study aims to evaluate whether the use of hyaluronic acid (hyaDENT BG®) in addition to standard surgical treatment improves clinical outcomes in patients with gingival recession. Participants will be randomly assigned to receive either standard treatment alone or standard treatment with hyaluronic acid.
The main outcome is the proportion of sites with complete root coverage after 12 months. Additional outcomes include healing, gum tissue improvement, patient-reported pain and discomfort, and aesthetic results.
The study also includes a laboratory component to investigate how hyaluronic acid affects cells involved in gum healing.
Detailed description
Gingival recession (GR) is a common mucogingival condition characterized by apical displacement of the gingival margin beyond the cemento-enamel junction, leading to root exposure, dentin hypersensitivity, increased risk of root caries, and aesthetic impairment. The coronally advanced flap combined with a subepithelial connective tissue graft (CAF + SCTG) is considered the gold standard for the treatment of single gingival recession defects, providing predictable root coverage and long-term stability. However, postoperative morbidity, donor-site discomfort, and incomplete root coverage may still occur.
Hyaluronic acid (HA) is a key component of the extracellular matrix with biological properties that promote wound healing, including stimulation of angiogenesis, cell migration, proliferation, and modulation of inflammatory responses. Cross-linked HA formulations exhibit prolonged bioactivity and may enhance soft tissue healing and regeneration in periodontal surgery.
This study is a prospective, randomized, controlled, post-market clinical follow-up (PMCF) trial designed to evaluate the clinical effectiveness and safety of adjunctive cross-linked hyaluronic acid (hyaDENT BG®) in combination with CAF + SCTG for the treatment of single RT1 and RT2 gingival recession defects. A total of 34 patients will be enrolled and randomly allocated in a 1:1 ratio to either the test group (CAF + SCTG with adjunctive HA) or the control group (CAF + SCTG alone). Randomization will be stratified by recession type (RT1 vs RT2), and outcome assessors will be blinded to treatment allocation.
The primary endpoint is complete root coverage (CRC) at 12 months, defined as recession depth equal to 0 mm relative to the cemento-enamel junction. Secondary endpoints include mean root coverage, recession reduction, clinical attachment level gain, probing depth reduction, keratinized tissue gain, early wound healing (Early Wound Healing Score), patient-reported outcomes (pain, discomfort, and oral health-related quality of life), and aesthetic outcomes assessed using the Root Coverage Esthetic Score (RES).
Clinical assessments will be performed at baseline and at predefined follow-up visits up to 12 months post-surgery using standardized protocols and calibrated examiners. Patient-reported outcomes will be collected using validated instruments, including visual analog scales (VAS) and the OHIP-14 questionnaire.
In parallel, an in vitro component will be conducted using primary human gingival fibroblasts isolated from connective tissue grafts obtained during surgery. These cells will be used to evaluate the effects of HA on cell viability, proliferation, migration, gene expression related to wound healing and inflammation, and activation of intracellular signaling pathways.
This combined clinical and translational approach aims to provide comprehensive evidence on both the clinical performance and biological mechanisms of action of hyaluronic acid in periodontal plastic surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CAF + SCTG + Hyaluronic Acid | Experimental | Procedure: Coronally Advanced Flap with Connective Tissue Graft, Device: Cross-linked Hyaluronic Acid GelParticipants undergo coronally advanced flap (CAF) surgery combined with a subepithelial connective tissue graft (SCTG) with adjunctive application of cross-linked hyaluronic acid (hyaDENT BG®). The graft is immersed in hyaluronic acid prior to placement, and the gel is applied to the recipient site before flap closure. |
| CAF + SCTG | Active comparator | Procedure: Coronally Advanced Flap with Connective Tissue GraftParticipants undergo coronally advanced flap (CAF) surgery combined with a subepithelial connective tissue graft (SCTG) without adjunctive hyaluronic acid. The graft is handled under standard conditions and hydrated with sterile saline prior to placement. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- - Age ≥ 18 years, in good general health (ASA I or II)
- Presence of a single gingival recession defect classified as RT1 or RT2
- Recession depth ≥ 2 mm with identifiable cemento-enamel junction (CEJ)
- Presence of at least 1 mm of keratinized tissue at the defect site
- No active periodontal disease (probing depth ≤ 4 mm and no bleeding on probing at the selected tooth)
Key exclusion criteria (13 listed)
- Uncontrolled systemic diseases (e.g., uncontrolled diabetes, severe cardiovascular disease, immunodeficiency)
- Pregnant or breastfeeding women
- Autoimmune diseases or immunosuppressive therapy
- Known hypersensitivity to hyaluronic acid
- Heavy smokers (>10 cigarettes/day) or recent tobacco use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronally Advanced Flap with Connective Tissue GraftAlso: CAF + SCTGStandard periodontal plastic surgery procedure for root coverage involving coronally advanced flap (CAF) combined with a subepithelial connective tissue graft (SCTG). The technique aims to cover exposed root surfaces and improve soft tissue thickness and stability. | Procedure or surgery | CAF + SCTG, CAF + SCTG + Hyaluronic Acid |
| Cross-linked Hyaluronic Acid GelAlso: hyaDENT BG®Application of cross-linked hyaluronic acid gel (hyaDENT BG®) as an adjunct to periodontal surgery. The gel is applied to the recipient site and used to immerse the connective tissue graft prior to placement, aiming to enhance soft tissue healing, promote cell proliferation and angiogenesis, and improve clinical outcomes. | Device | CAF + SCTG + Hyaluronic Acid |
Primary outcome
Complete Root Coverage (CRC)
Time frame: 12 months
Proportion of treated sites achieving complete root coverage, defined as recession depth equal to 0 mm relative to the cemento-enamel junction, assessed using a calibrated periodontal probe by a blinded examiner.
10 secondary outcomes
Mean Root Coverage (MRC)
Time frame: 12 months
Recession Reduction (RecRed)
Time frame: 12 months
Clinical Attachment Level (CAL) Gain
Time frame: 12 months
Probing Depth (PD) Reduction
Time frame: 12 months
Keratinized Tissue Width (KT) Gain
Time frame: 12 months
Early Wound Healing Score (EHS)
Time frame: 3 days, 14 days, and 6 weeks
Postoperative Pain and Discomfort (VAS)
Time frame: 3 days, 14 days, and 6 weeks
Oral Health-Related Quality of Life (OHIP-14)
Time frame: 3 days, 14 days, and 6 weeks
Root Coverage Esthetic Score (RES)
Time frame: 12 months
Surgical and Postoperative Complications
Time frame: up to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Background: PubMed 32368762Guldener K, Lanzrein C, Eliezer M, Katsaros C, Stahli A, Sculean A. Treatment of single mandibular recessions with the modified coronally advanced tunnel or laterally closed tunnel, hyaluronic acid, and subepithelial connective tissue graft: a report of 12 cases. Quintessence Int. 2020;51(6):456-463. doi: 10.3290/j.qi.a44492.
- Background: PubMed 30264516Asparuhova MB, Kiryak D, Eliezer M, Mihov D, Sculean A. Activity of two hyaluronan preparations on primary human oral fibroblasts. J Periodontal Res. 2019 Feb;54(1):33-45. doi: 10.1111/jre.12602. Epub 2018 Sep 27.
- Background: PubMed 29961138Pilloni A, Schmidlin PR, Sahrmann P, Sculean A, Rojas MA. Effectiveness of adjunctive hyaluronic acid application in coronally advanced flap in Miller class I single gingival recession sites: a randomized controlled clinical trial. Clin Oral Investig. 2019 Mar;23(3):1133-1141. doi: 10.1007/s00784-018-2537-4. Epub 2018 Jun 30.
- Individual participant dataSharing planned: Undecided. No final decision has been made regarding individual participant data sharing. Data sharing will be considered in accordance with applicable regulations and institutional policies.
Related trials for Gingival Recession, Mucogingival Surgery
Recruiting
Effects of Low-Level Laser Therapy and Hyaluronic Acid After Free Gingival Graft
Gingival Recession, Mucogingival Surgery
Not yet recruiting
Evaluation of the Effects of Injectable Platelet-Rich Fibrin and Hyaluronic Acid Treatments, Administered in Addition to Free Gingival Graft Therapy, on Clinical Healing.
Lack of Keratinized Tissue, Mucogingival Surgery
Active, not recruiting
V-Reverse Suture Technique Compared to Traditional Anchored Sling Suture in Treating Multiple Gingival Recession
Gingival Recession, Mucogingival Surgery
Recruiting
Comparison of Two Methods of Covering a Single Lower Front Tooth With Receded Gums
Recession, Gingival
Recruiting
Management of Postoperative Pain Following Free Gingival Graft Harvesting Using Ora-Aid Versus Acrylic Palatal Stent
Postoperative Pain, Mucogingival Defects
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Coronally Advanced Flap with Connective Tissue Graft and Cross-linked Hyaluronic Acid Gel in people with Gingival Recession, Mucogingival Surgery, run by Universidade do Porto at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marta M Abreu-Costa (+351911834256, martacostaa11@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete Root Coverage (CRC) (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07529340, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.